Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
24.99
-0.40 (-1.58%)
Bozor ochiq: Aug 12, 2026, 1:44 PM EDT
26.09
+0.70 (2.76%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Adaptive Biotechnologies Corporation, tijorat bosqichidagi kompaniya, turli kasalliklarni tashxislash va davolash uchun immunitet tibbiyoti platformasini ishlab chiqadi. Kompaniya immunitet tizimini tushunish uchun klinik immunomika ma'lumotlarini yaratish uchun patentlangan kimyo, hisoblash biologiyasi va mashinani o'rganish to'plamini birlashtirgan immunosekvenlash platformasini taklif etadi. U bemorning davolanish paytida va undan keyin uning tanasida mavjud bo'lgan saraton hujayralari sonini aniqlaydigan va kuzatadigan clonoSEQ diagnostika testini taqdim etadi, bu Minimal Qoldiq Kasallik (MRD) deb nomlanadi. Kompaniya hayot haqidagi fanlar tadqiqotlari, klinik diagnostika va dori-darmonlarni kashf qilish dasturlari uchun mahsulot va xizmatlarni taklif etadi. Kompaniya ilgari Adaptive TCR Corporation nomi bilan tanilgan va 2011 yil dekabr oyida Adaptive Biotechnologies Corporation nomini o'zgartirgan. Adaptive Biotechnologies Corporation 2009 yilda ro'yxatga olingan va Sietl, Vashingtonda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Sharon Benzeno Ph.D. | Chief Commercial Officer of Immune Medicine |
| Mr. Chad M. Robins M.B.A. | Co-Founder, CEO & Chairman |
| Mr. Christopher Carlson Ph.D. | Founder |
| Mr. Francis T. Lo | Chief People Officer |
| Mr. Kyle Piskel | VP, CFO & Principal Accounting Officer |
| Ms. Clarice McCauley | Head of Legal, Corporate Secretary, VP & Chief Compliance Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-04 | 10-Q | adpt-20260630.htm |
| 2026-07-29 | 8-K | adpt-20260724.htm |
| 2026-06-22 | 8-K | d28937d8k.htm |
| 2026-06-15 | 8-K | d65233d8k.htm |
| 2026-06-09 | 8-K | adpt-20260605.htm |
| 2026-05-05 | 8-K | adpt-20260505.htm |
| 2026-05-05 | 10-Q | adpt-20260331.htm |
| 2026-04-24 | DEFA14A | adpt_defa_14a.htm |
| 2026-04-24 | DEF 14A | adpt-20260423.htm |
| 2026-04-24 | ARS | adpt_ars_2026.pdf |
| Ms. Julie Rubinstein | President & COO |
| Ms. Karina Calzadilla | VP of Investor Relations and FP&A |
| Ms. Mary Pat Lancelotta | Senior Vice President of MRD BioPharma |
| Ms. Susan Bobulsky | Chief Commercial Officer of MRD |